Rosen Law Firm, a global investor rights law firm, announced on December 26 that it was investigating potential securities claims on behalf of shareholders of Sinovac Biotech Ltd. (NASDAQ: SVA) resulting from allegations that Sinovac may have issued materially misleading business information to the investing public.

On December 21, 2016, an article published on SeekingAlpha.com revealed that according to a recent Beijing court judgment, the Chairman and CEO of Sinovac, Weidong Ying, paid bribes to Yin Hongzhang, the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration, and his wife, in order to help advance drug applications and evaluations.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Sinovac investors. Sinovac investors can visit the firm’s website at http://www.rosenlegal.com/cases-1015.html for more information. Otherwise Phillip Kim or Kevin Chan of Rosen Law Firm can be reached toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.